REPLIMUNE GROUP INC. - COMMON STOCK

Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma

21 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 Jan 2025 15:01:00 By Nasdaq GlobeNewswire

Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical Trials

08 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference

23 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

Replimune Announces Pricing of Upsized Public Offering

25 Nov 2024 22:55:49 By Nasdaq GlobeNewswire

Replimune Announces Proposed Public Offering

25 Nov 2024 06:09:26 By Nasdaq GlobeNewswire

Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway

21 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update

12 Nov 2024 07:00:02 By Nasdaq GlobeNewswire

Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)

09 Nov 2024 12:00:00 By Nasdaq GlobeNewswire

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

08 Nov 2024 15:01:00 By Nasdaq GlobeNewswire

Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

30 Oct 2024 08:15:09 By Nasdaq GlobeNewswire

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

09 Oct 2024 15:01:00 By Nasdaq GlobeNewswire

Replimune to Present at Two Upcoming Investor Conferences

01 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024

15 Sep 2024 08:45:00 By Nasdaq GlobeNewswire

Replimune Announces Positive Pre-BLA Meeting with FDA and Confirms BLA Submission On Track for 2H 2024

09 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Stockholders Vote to Elect Madhavan Balachandran to Board of Directors

05 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Replimune Announces Late-Breaking Abstract of IGNYTE Clinical Trial Primary Analysis Selected for Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2024

22 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma

13 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Replimune Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update

08 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Replimune to Present at Two Upcoming Investor Conferences

30 Jul 2024 15:01:00 By Nasdaq GlobeNewswire